Back to top

Image: Bigstock

Gear Up for Illumina (ILMN) Q2 Earnings: Wall Street Estimates for Key Metrics

Read MoreHide Full Article

The upcoming report from Illumina (ILMN - Free Report) is expected to reveal quarterly earnings of $1.02 per share, indicating an increase of 183.3% compared to the year-ago period. Analysts forecast revenues of $1.05 billion, representing a decline of 5.8% year over year.

The consensus EPS estimate for the quarter has undergone a downward revision of 0.2% in the past 30 days, bringing it to its present level. This represents how the covering analysts, as a whole, have reassessed their initial estimates during this timeframe.

Before a company announces its earnings, it is essential to take into account any changes made to earnings estimates. This is a valuable factor in predicting the potential reactions of investors toward the stock. Empirical research has consistently shown a strong correlation between trends in earnings estimate revisions and the short-term price performance of a stock.

While investors typically use consensus earnings and revenue estimates as a yardstick to evaluate the company's quarterly performance, scrutinizing analysts' projections for some of the company's key metrics can offer a more comprehensive perspective.

That said, let's delve into the average estimates of some Illumina metrics that Wall Street analysts commonly model and monitor.

Analysts forecast 'Revenue- Core Illumina- Consumables' to reach $792.14 million. The estimate points to a change of -2.8% from the year-ago quarter.

The consensus among analysts is that 'Revenue- Product revenue- Consumable' will reach $788.41 million. The estimate indicates a change of -3.3% from the prior-year quarter.

It is projected by analysts that the 'Revenue- Service and other revenue' will reach $157.99 million. The estimate points to a change of -14.6% from the year-ago quarter.

Analysts expect 'Revenue- Product revenue' to come in at $888.52 million. The estimate indicates a change of -4.2% from the prior-year quarter.

The average prediction of analysts places 'Revenue- Core Illumina- Service and other revenue' at $159.52 million. The estimate suggests a change of +1.6% year over year.

Based on the collective assessment of analysts, 'Revenue- Core Illumina- Total product revenue' should arrive at $886.54 million. The estimate suggests a change of -5.2% year over year.

The collective assessment of analysts points to an estimated 'Revenue- Product revenue- Instruments' of $115.79 million. The estimate points to a change of -3.5% from the year-ago quarter.

According to the collective judgment of analysts, 'Revenue- Core Illumina- Instruments' should come in at $94.40 million. The estimate suggests a change of -21.3% year over year.

Analysts predict that the 'Revenue by Source- Total product revenue- Sequencing' will reach $802.27 million. The estimate points to a change of -19.5% from the year-ago quarter.

The consensus estimate for 'Revenue- Sequencing- Instruments' stands at $111.69 million. The estimate indicates a change of -3.7% from the prior-year quarter.

The combined assessment of analysts suggests that 'Revenue- Sequencing- Consumables' will likely reach $705.59 million. The estimate indicates a change of -4.3% from the prior-year quarter.

Analysts' assessment points toward 'Revenue- Microarrays- Instruments' reaching $3.45 million. The estimate indicates a change of -13.9% from the prior-year quarter.

View all Key Company Metrics for Illumina here>>>

Shares of Illumina have experienced a change of +10.8% in the past month compared to the +3.4% move of the Zacks S&P 500 composite. With a Zacks Rank #3 (Hold), ILMN is expected to mirror the overall market performance in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .


See More Zacks Research for These Tickers


Normally $25 each - click below to receive one report FREE:


Illumina, Inc. (ILMN) - free report >>

Published in